|dc.contributor.author||Eltarhoni, Mohamed G||
|dc.description||Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with
onset or first recognition during pregnancy . It is observed in 7–18% of pregnancies and is
associated with an increased risk of a variety of maternal and perinatal complications,
including preeclampsia, Caesarean section, shoulder dystocia, birth injuries, hypoglycaemia
and respiratory distress syndrome (RDS) .
Metformin is an anti-hyperglycaemic agent reduces hyperglycaemia by suppressing hepatic
glucose output (hepatic gluconeogenesis), increasing insulin sensitivity and enhancing
peripheral glucose uptake. Implementation of metformin should be in conjunction with diet
and exercise for glycemic control. The U.S. Food and Drug Administration categorizes this
medication as a class B drug in pregnancy; however, it cautions that metformin can cross the
placenta and should not be used during pregnancy unless clearly needed. Despite these
concerns, metformin appears to be an alternative option for the treatment of GDM||en_US
|dc.description.abstract||Gestational diabetes is glucose intolerance identified in the second trimester of pregnancy.
This occurs mainly due to the diabetogenic effects of placental hormones and is associated
with certain critical fetal and maternal consequences.
If maternal normoglycaemia cannot be achieved by diet and lifestyle changes, medication
will be needed. The standard treatment for achieving adequate glucose levels is insulin
therapy. However, the disadvantages of insulin for the mother include the need for injections,
risk of hypoglycaemia, increased appetite and weight gain. Furthermore, this treatment
requires modification based on the patient's body mass index, glucose levels and lifestyle .
Metformin appears to be a viable option for use in GDM. This medication with a different
mode of action from insulin is an antihyperglycemic agent Its primary mechanism of action
is in reducing hepatic glucose production. Secondarily, it decreases intestinal absorption of
glucose and improves insulin sensitivity by increasing peripheral glucose uptake and
utilization and does not cause either hypoglycemia or hyperinsulinemia||en_US
|dc.publisher||faculty of Basic Medical Science - Libyan International Medical University||en_US
|dc.rights||Attribution 3.0 United States||*
|dc.title||The Effect of Metformin in Gestational Diabetes||en_US